China Focus @Bio
Date：Jun 2, 2019
Venue：Loews Philadelphia Hotel, 1200 Market St, Philadelphia, PA 19107
About China Focus @ BIO Philadelphia
The event features premier 1-to-1 networking opportunities prior to and during the forum, which brings together 100+ Chinese investors and pharma leaders, and healthcare innovators. It is designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.
Echo Hindle-Yang, Founder & CEO at MSQ Ventures was honored to moderate a discussion panel regarding the topic, ‘Potential Collaboration with Chinese Pharma’.
Main Topics Highlight:
- Cross-border Investment: Money from the East and the West
- Innovations Going to China: Regulation, Market Access, Manufacturing and Distribution
- Chinese Innovations Going West: Partnership for Capital and Market Access in the U.S.
- Chinese life science and healthcare industry overview and collaboration potential
- AI and Pharmaceutical synergies, current situation and trends
AI and Digital Health Forum
Echo Hindle-Yang – CEO, MSQ Ventures was the “AI and Digital Health Forum” panel moderator. She shared insights on how AI would benefit the pharma industry. The panel pointed out that healthcare became an emerging and prominent area for AI research and applications. As AI biotech startups emerged, traditional pharma companies were experimenting with AI technique for innovative solutions, including discovering and screening new drug candidates, identifying new indications, and predicting drug performance…etc.
The panel also highlighted the vast opportunities for healthcare AI in China. Along with a discussion on the Chinese government’s new policy on AI last year, which set the course for China to become a global AI research leader by 2030. Healthcare was one of the main focus areas for China’s first wave of AI application. With government support, Chinese healthcare AI would be the new rising star.
In the private market, Chinese healthcare AI deals had surpassed the UK in the first half of 2018 and became the second most active country for healthcare AI deals. Chinese investors have been increasingly invested in healthcare AI companies, both in domestic and overseas crossing seeds stage to series D. They have been actively seeking strategic partners and investors. Leading Chinese tech giants entered into healthcare AI through utilizing its broad customer network, as well as global partnership to develop healthcare AI products and services.